Pharma BD Deal Intelligence

Abbott Laboratories / Facet Biotech Corporation

2010 · Acquisition/Merger · $722M · Complete

Announcement Sentiment

Neutral / mixed

Abbott to acquire Facet Biotech for $27/share cash (~$722M gross, ~$450M net of Facet's cash). Adds daclizumab Phase II MS biologic and oncology compounds. Closed April 21, 2010.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 15yr post-close.

Key facts

Announced Mar 09, 2010
Closed Apr 21, 2010
Deal value $722M
Deal type Acquisition/Merger
Therapeutic area Multiple sclerosis
Indications Multiple sclerosis
Key assets Daclizumab (DAC HYP)
Mechanism Anti-CD25 monoclonal antibody (humanized)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals